Clinical Trials Browser

disitamab vedotin × Gastrointestinal × Clear all

NCT07509424 2026-04-03

Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance

Phase 2 Not yet recruiting

Gastrointestinal

Rectal Neoplasms

NCT07507526 2026-04-02

DTP-HER2

Phase 2 Not yet recruiting

Gastrointestinal

Gastric Adenocarcinoma

NCT07490990 2026-03-24

A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure

Not yet recruiting

Gastrointestinal

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

NCT06157892 2026-03-17

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Phase 2 Recruiting

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07315750 2026-01-21

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05980481 2025-09-29

A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric Cancer

Phase 2/3 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT07159217 2025-09-08

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT05586061 2025-02-07

RCTS

Phase 2 Active not recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT06730373 2024-12-31

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06650332 2024-10-21

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Phase 1/2 Recruiting

Gastrointestinal

Metastatic HER2 Positive Gastroesophageal Junction Cancer

NCT06560528 2024-08-19

Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06492317 2024-07-09

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Phase 2 Not yet recruiting

Gastrointestinal

HER2-positive Gastric Cancer

NCT06385873 2024-05-13

RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Stomach Neoplasms

NCT06233864 2024-04-17

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06221748 2024-04-03

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Phase 2/3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT06155383 2023-12-14

Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase 2 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT05578287 2023-12-07

DETECT

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT06078982 2023-10-12

Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer

Phase 1 Unknown

Gastrointestinal

Stomach Neoplasms

NCT05649163 2022-12-16

Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy

GastrointestinalOther solid neoplasm

HER2

NCT05627414 2022-11-25

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Phase 2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT05493683 2022-10-21

Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms

NCT05333809 2022-04-20

Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer

Phase 2 Unknown

Gastrointestinal

Colorectal Neoplasms